AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Research Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer

Pengyuan Liu1,3,§, Yajun Wu1,6,§, Xiaogang Xu4,§, Xudong Fan2,§, Chuan Sun4, Xiaojie Chen2, Jindan Xia1, Shiting Bai1, Li Qu7, Huasong Lu5, Jing Wu1,3, Jun Chen1( ), Ji-Gang Piao2( ), Zhibing Wu1,3( )
Department of Oncology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou 310013, China
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
Department of Radiation Oncology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou 310013, China
Geriatrics Institute of Zhejiang Province, Department of Geriatrics, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou 310030, China
Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou 310058, China
TCM Dispensary, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou 310013, China
Department of Breast Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China

§ Pengyuan Liu, Yajun Wu, Xiaogang Xu, and Xudong Fan contributed equally to this work.

Show Author Information

Graphical Abstract

This study reports the development of cmHSP70-PL-AuNC-DOX, a tumor-targeting nanoplatform consisting of a thermosensitive lipid-coated gold nanocage, heat shock protein 70 monoclonal antibody, and chemotherapeutic drug doxorubicin, for precise targeting treatment of castration-resistant prostate cancer.

Abstract

Lacking a precise targeting strategy, castration-resistant prostate cancer (CRPC) is still hard to be treat effectively. Exploring treatment options that can accurately target CPRC is an important issue with urgent need. In this study, a novel nanotechnology-based strategy had been developed for the precise target treatment of CRPC. By combining microwaves and photothermal therapy (PTT), this nanoplatform, cmHSP70-PL-AuNC-DOX, targets tumor tissues with outstanding precision and achieves better anti-tumor activity by simultaneously eliciting photothermal and chemotherapeutic effects. From nanotechnology, cmHSP70-modified and thermo-sensitive liposome-coated AuNC-DOX were prepared and used for CRPC-targeted photothermal ablation and chemotherapy. Doxorubicin (DOX) was selected as the chemotherapeutic agent for cytotoxicity. In terms of the curative scheme, prostate tissues were firstly pre-treated with microwaves to induce the expression of heat shock protein 70 (HSP70) and its migration to the cell membrane, which was then targeted by HSP70 antibody (cmHSP70) coated on the nanoparticles to achieve accurate drug delivery. The nanoplatform then achieved precise ablation and controlled release of DOX under external near-infrared (NIR) irradiation. Through the implementation, the targeting, cell killing, and safety of this therapeutical strategy had been verified in vivo and in vitro. This work establishes an accurate, controllable, efficient, non-invasive, and safe treatment platform for targeting CRPC, provides a rational design for CRPC’s PTT, and offers new prospects for nanomedicines with great precision.

Keywords

targeted drug deliverycastration-resistant prostate cancergold nanocageheat shock protein 70photothermal-chemotherapy

Electronic Supplementary Material

Download File(s)
12274_2023_5541_MOESM1_ESM.pdf (668.7 KB)

References

[1]

Siegel, R. L.; Miller, K. D.; Fuchs, H. E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33.
Crossref Google Scholar
[2]

Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G. et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur. Urol. 2021, 80, 275–279.
Crossref Google Scholar
[3]

Petrylak, D. P.; Ratta, R.; Gafanov, R.; Facchini, G.; Piulats, J. M.; Kramer, G.; Flaig, T. W.; Chandana, S. R.; Li, B.; Burgents, J. et al. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021, 17, 3291–3299.
Crossref Google Scholar
[4]

Cornford, P.; van den Bergh, R. C. N.; Briers, E.; van den Broeck, T.; Cumberbatch, M. G.; de Santis, M.; Fanti, S.; Fossati, N.; Gandaglia, G.; Gillessen, S. et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur. Urol. 2021, 79, 263–282.
Crossref Google Scholar
[5]

Teo, M. Y.; Rathkopf, D. E.; Kantoff, P. Treatment of advanced prostate cancer. Annu. Rev. Med. 2019, 70, 479–499.
Crossref Google Scholar
[6]

Mansinho, A.; Macedo, D.; Fernandes, I.; Costa, L. Castration-resistant prostate cancer: Mechanisms, targets and treatment. Adv. Exp. Med. Biol. 2018, 1096, 117–133.
Crossref Google Scholar
[7]

Komura, K.; Sweeney, C. J.; Inamoto, T.; Ibuki, N.; Azuma, H.; Kantoff, P. W. Current treatment strategies for advanced prostate cancer. Int. J. Urol. 2018, 25, 220–231.
Crossref Google Scholar
[8]

Barata, P. C.; Sartor, A. O. Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…. Cancer 2019, 125, 1777–1788.
Crossref Google Scholar
[9]

Satapathy, S.; Mittal, B. R.; Sood, A.; Das, C. K.; Mavuduru, R. S.; Goyal, S.; Shukla, J.; Singh, S. K. 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer:A randomized, controlled, phase 2 non-inferiority trial. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 1754–1764.
Crossref Google Scholar
[10]

Hofman, M. S.; Emmett, L.; Sandhu, S.; Iravani, A.; Joshua, A. M.; Goh, J. C.; Pattison, D. A.; Tan, T. H.; Kirkwood, I. D.; Ng, S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet 2021, 397, 797–804.
Crossref Google Scholar
[11]

Ruiz de Porras, V.; Font, A.; Aytes, A. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett. 2021, 523, 162–169.
Crossref Google Scholar
[12]

Bansal, D.; Reimers, M. A.; Knoche, E. M.; Pachynski, R. K. Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers 2021, 13, 334.
Crossref Google Scholar
[13]

Handy, C. E.; Antonarakis, E. S. Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions. Future Oncol. 2018, 14, 907–917.
Crossref Google Scholar
[14]

Wei, X. X.; Kwak, L.; Hamid, A.; He, M.; Sweeney, C.; Flanders, S. C.; Harmon, M.; Choudhury, A. D. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: Experience at dana Farber and in the PROCEED registry. Prostate Cancer Prostatic Dis. 2022, 25, 314–319.
Crossref Google Scholar
[15]

Hawley, J. E.; Pan, S.; Kandadi, H.; Chaimowitz, M. G.; Sheikh, N.; Drake, C. G. Analysis of circulating immune biomarkers by race in men with metastatic castration-resistant prostate cancer treated with sipuleucel-T. J. Natl. Cancer Inst. 2022, 114, 314–317.
Crossref Google Scholar
[16]

Kantoff, P. W.; Higano, C. S.; Shore, N. D.; Berger, E. R.; Small, E. J.; Penson, D. F.; Redfern, C. H.; Ferrari, A. C.; Dreicer, R.; Sims, R. B. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411–422.
Crossref Google Scholar
[17]

Sweeney, C.; Bracarda, S.; Sternberg, C. N.; Chi, K. N.; Olmos, D.; Sandhu, S.; Massard, C.; Matsubara, N.; Alekseev, B.; Parnis, F. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2021, 398, 131–142.
Crossref Google Scholar
[18]

Posdzich, P.; Darr, C.; Hilser, T.; Wahl, M.; Herrmann, K.; Hadaschik, B.; Grünwald, V. Metastatic prostate cancer-a review of current treatment options and promising new approaches. Cancers 2023, 15, 461.
Crossref Google Scholar
[19]

Kotani, N.; Wilkins, J. J.; Wade, J. R.; Dang, S.; Sutaria, D. S.; Yoshida, K.; Sundrani, S.; Ding, H.; Garcia, J.; Hinton, H. et al. Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study. Cancer Chemother. Pharmacol. 2022, 90, 511–521.
Crossref Google Scholar
[20]

Gasmi, A.; Roubaud, G.; Dariane, C.; Barret, E.; Beauval, J. B.; Brureau, L.; Créhange, G.; Fiard, G.; Fromont, G.; Gauthé, M. et al. Overview of the development and use of akt inhibitors in prostate cancer. J. Clin. Med. 2021, 11, 160.
Crossref Google Scholar
[21]

Zhang, T.; George, D. J.; Armstrong, A. J. Precision medicine approaches when prostate cancer akts up. Clin. Cancer Res. 2019, 25, 901–903.
Crossref Google Scholar
[22]

Kessel, K.; Bernemann, C.; Bögemann, M.; Rahbar, K. Evolving castration resistance and prostate specific membrane antigen expression: Implications for patient management. Cancers 2021, 13, 3556.
Crossref Google Scholar
[23]

Emmett, L.; Buteau, J.; Papa, N.; Moon, D.; Thompson, J.; Roberts, M. J.; Rasiah, K.; Pattison, D. A.; Yaxley, J.; Thomas, P. et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study. Eur. Urol. 2021, 80, 682–689.
Crossref Google Scholar
[24]

Yamada, Y.; Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 2021, 23, 15.
Crossref Google Scholar
[25]

Ferroni, C.; Del Rio, A.; Martini, C.; Manoni, E.; Varchi, G. Light-induced therapies for prostate cancer treatment. Front. Chem. 2019, 7, 719.
Crossref Google Scholar
[26]

Shi, X. L.; Tian, Y.; Liu, Y.; Xiong, Z. R.; Zhai, S. B.; Chu, S. L.; Gao, F. X. Research progress of photothermal nanomaterials in multimodal tumor therapy. Front. Oncol. 2022, 12, 939365.
Crossref Google Scholar
[27]

Milan, J.; Niemczyk, K.; Kus-Liśkiewicz, M. Treasure on the earth-gold nanoparticles and their biomedical applications. Materials 2022, 15, 3355.
Crossref Google Scholar
[28]

Wang, Y.; Li, J.; Li, X. B.; Shi, J. P.; Jiang, Z. T.; Zhang, C. Y. Graphene-based nanomaterials for cancer therapy and anti-infections. Bioact. Mater. 2022, 14, 335–349.
Crossref Google Scholar
[29]

Rastinehad, A. R.; Anastos, H.; Wajswol, E.; Winoker, J. S.; Sfakianos, J. P.; Doppalapudi, S. K.; Carrick, M. R.; Knauer, C. J.; Taouli, B.; Lewis, S. C. et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proc. Natl. Acad. Sci. USA 2019, 116, 18590–18596.
Crossref Google Scholar
[30]

Hwang, E.; Jung, H. S. Organelle-targeted photothermal agents for cancer therapy. Chem. Commun. 2021, 57, 7731–7742.
Crossref Google Scholar
[31]

Ren, Y. T.; Yan, Y. Y.; Qi, H. Photothermal conversion and transfer in photothermal therapy: From macroscale to nanoscale. Adv. Colloid Interface Sci. 2022, 308, 102753.
Crossref Google Scholar
[32]

Kalyane, D.; Raval, N.; Maheshwari, R.; Tambe, V.; Kalia, K.; Tekade, R. K. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater. Sci. Eng. C 2019, 98, 1252–1276.
Crossref Google Scholar
[33]

Shinde, V. R.; Revi, N.; Murugappan, S.; Singh, S. P.; Rengan, A. K. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis. Photodyn. Ther. 2022, 39, 102915.
Crossref Google Scholar
[34]

Shekhar, S.; Chauhan, M.; Sonali, Yadav, B.; Dutt, R.; Hu, L. D.; Muthu, M. S.; Singh, R. P. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: Latest trends, obstacles and future perspective. Nanomedicine 2022, 17, 1213–1216.
Crossref Google Scholar
[35]

Wang, Y. C.; Liu, Y. J.; Luehmann, H.; Xia, X. H.; Brown, P.; Jarreau, C.; Welch, M.; Xia, Y. N. Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging. ACS Nano 2012, 6, 5880–5888.
Crossref Google Scholar
[36]

Pan, P.; Svirskis, D.; Rees, S. W. P.; Barker, D.; Waterhouse, G. I. N.; Wu, Z. M. Photosensitive drug delivery systems for cancer therapy: Mechanisms and applications. J. Control. Release 2021, 338, 446–461.
Crossref Google Scholar
[37]

Yang, C. B.; Lin, Z. I.; Chen, J. A.; Xu, Z. R.; Gu, J. Y.; Law, W. C.; Yang, J. H. C.; Chen, C. K. Organic/inorganic self-assembled hybrid nano-architectures for cancer therapy applications. Macromol. Biosci. 2022, 22, e2100349.
Crossref Google Scholar
[38]

Robinson, R.; Gerlach, W.; Ghandehari, H. Comparative effect of gold nanorods and nanocages for prostate tumor hyperthermia. J. Control. Release 2015, 220, 245–252.
Crossref Google Scholar
[39]

Qiu, J. C.; Liu, Y. J.; Xia, Y. N. Radiolabeling of gold nanocages for potential applications in tracking, diagnosis, and image-guided therapy. Adv. Healthc. Mater. 2021, 10, 2002031.
Crossref Google Scholar
[40]

Park, J. H.; Seo, H.; Kim, D. I.; Choi, J. H.; Son, J. H.; Kim, J.; Moon, G. D.; Hyun, D. C. Gold nanocage-incorporated poly(ε-caprolactone) (PCL) fibers for chemophotothermal synergistic cancer therapy. Pharmaceutics 2019, 11, 60.
Crossref Google Scholar
[41]

He, H. M.; Liu, L. L.; Zhang, S. P.; Zheng, M. B.; Ma, A. Q.; Chen, Z.; Pan, H.; Zhou, H. M.; Liang, R. J.; Cai, L. T. Smart gold nanocages for mild heat-triggered drug release and breaking chemoresistance. J. Control. Release 2020, 323, 387–397.
Crossref Google Scholar
[42]

Cheng, Y.; Bao, D. D.; Chen, X. J.; Wu, Y. J.; Wei, Y. H.; Wu, Z. B.; Li, F. Z.; Piao, J. G. Microwave-triggered/HSP-targeted gold nano-system for triple-negative breast cancer photothermal therapy. Int. J. Pharm. 2021, 593, 120162.
Crossref Google Scholar
Nano Research
Volume 16 Issue 7,
July 2023
Pages 9688-9700
DOI: 10.1007/s12274-023-5541-1
Cite this article:
Liu P, Wu Y, Xu X, et al. Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer. Nano Research, 2023, 16(7): 9688-9700. https://doi.org/10.1007/s12274-023-5541-1
Topics:
Targeted drug delivery

1056

Views

6

Crossref

5

Web of Science

5

Scopus

0

CSCD

Altmetrics
Received: 29 October 2022
Revised: 27 January 2023
Accepted: 02 February 2023
Published: 27 February 2023
© Tsinghua University Press 2023
Return